Literature DB >> 2202335

Ocular cicatricial pemphigoid.

I C Francis1, P J McCluskey, R S Walls, D Wakefield, J M Brewer.   

Abstract

A series of 17 patients with ocular cicatricial pemphigoid (OCP) is described retrospectively. The importance of early recognition, especially of disease involving the medial canthus and caruncular region, diagnosis by biopsy, and adequate immunosuppressive and surgical therapy, are emphasised. A detailed grading scheme has been developed and this has enabled the authors to determine the success or failure of the therapy during the active treatment period. A combined ophthalmological and immunological approach to treatment can result in a successful visual outcome of this potentially blinding disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2202335     DOI: 10.1111/j.1442-9071.1990.tb00605.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  5 in total

1.  Local interferon alfa-2b for ocular cicatricial pemphigoid.

Authors:  M Gillies; I Francis; P McCluskey; D Wakefield
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

2.  Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.

Authors:  M J Elder; J Leonard; J K Dart
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

3.  Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid.

Authors:  M J Elder; J K Dart; R Collin
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

Review 4.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

5.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.